The Weekly Roundup: January 5-9

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

The Evolving Evidence Base in Hyperhidrosis Care

Explore the latest insights on hyperhidrosis, its impact on quality of life, and advancements in effective treatment options for this often-overlooked condition.

First Patient Dosed in Phase 2 Trial of Anti–IL-11 Antibody for Pathological Scarring

Mabwell’s investigational 9MW3811 is the first IL-11–targeting therapy to enter clinical evaluation for pathological scarring.

French Guidelines Updated to Reflect Advances in Systemic Psoriasis Therapy

Explore the latest French guidelines for systemic psoriasis therapy, highlighting new treatments and tailored management strategies for diverse patient needs.

New Analysis Clarifies the Dermatologic Risks of GLP-1 RA Therapy

Explore the latest findings on GLP-1 RA injection-site and dermatologic reactions, enhancing treatment adherence and patient counseling strategies.

Hands in Distress: The Daily Burden of Chronic Hand Eczema

Izabela Horzempa, PA-C, analyzes the challenges of CHE and shares innovative treatment options that enhance patient quality of life and management strategies.

1550 nm Laser Demonstrates Efficacy in Acne Scar Treatment Across All Skin Types

Discover how a novel 1550 nm laser treatment effectively addresses acne scarring in diverse skin types, enhancing safety and results for all.

Dermatology Market Update 2026: Second Bites, Regulatory Headwinds, and the Flight Toward Scale

Dermatology investment trends shift as private equity re-enters the market, focusing on practices with strong infrastructure and clinical excellence.

Patients Over 60 Face Increasing Melanoma Risk as Global Burden Shifts

Elderly populations are facing rising cutaneous malignant melanoma incidence and mortality, highlighting urgent needs for targeted prevention and early detection strategies in skin cancer care.

New Study Reveals High Rates of Addiction Among Patients with Psoriasis and Other Conditions

Chronic skin diseases like psoriasis and AD are linked to high smoking and other addiction rates, highlighting the need for integrated psychosocial support.

Phase 3 Data Support Oral TYK2 Inhibitor Envudeucitinib for Psoriasis

Envudeucitinib shows promising results as a new oral therapy for psoriasis, achieving high skin clearance rates and rapid symptom improvement in clinical trials.

Deciphering Evolving Biologic Strategies for Hidradenitis Suppurativa

At the Dermatology Times Horizons in Advanced Practice meeting in Tampa, Florida, conference chair Lakshi Aldredge, MSN, ANP-BC, DCNP, focused a discussion on efficacy data for adalimumab, secukinumab, and bimekizumab.

Precision Dermatology: Aligning Immune Pathways with Therapy

Explore how precision dermatology leverages immune pathways to enhance treatment for inflammatory skin diseases.

Journal Digest: January 7, 2026

This review of the latest dermatologic studies includes insights on dupilumab-associated rosacea, the prevalence of young adult acne, psoriasis patients with acute coronary syndrome, and more.

Expert Consensus Redefines the Role of Systemic Corticosteroids in AD

Expert consensus clarifies systemic corticosteroid use in atopic dermatitis, emphasizing risks and advocating for advanced therapies for better patient outcomes.

Legacy Healthcare Receives FDA Clearance to Advance Cinainu to Phase 3 AA Clinical Trials

Legacy Healthcare has advanced Cinainu into phase 3 study for alopecia areata, offering hope for effective, safe treatment without immunosuppression.

First-in-Class FcRn Inhibitor Nipocalimab Meets Primary Endpoint in Phase 2b Study for Active SLE

Johnson & Johnson's nipocalimab shows promise in reducing systemic lupus erythematosus activity, paving the way for a phase 3 development program.

Phase 1b Asthma Data Highlight Durable IL-13 Suppression with Zumilokibart

Apogee Therapeutics reveals promising phase 1b trial results for zumilokibart, highlighting its potential as a durable treatment for atopic dermatitis.

Botanical Therapies for Acne: A Clinical Review of Social Media Trends

Explore the effectiveness of herbal acne therapies versus social media trends, revealing both promising treatments and potential misinformation risks.

First Patient Dosed in Phase 3 VP-102 Common Warts Program

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.

Interim Analysis Leads to Early Termination of DUPLEX-AD Study

Johnson & Johnson reveals JNJ-95475939's early termination due to insufficient efficacy in treating moderate-to-severe atopic dermatitis.

Jasper Therapeutics Announces Positive Updated Phase 1b/2a Data for Briquilimab in CSU

Jasper Therapeutics reveals promising briquilimab data, showcasing rapid disease control and safety in chronic spontaneous urticaria and chronic inducible urticaria.

Assessing the Global Impact of Chronic Spontaneous Urticaria on Family and Caregivers

CSU significantly impacts family quality of life, revealing the need for comprehensive care and support for both patients and their caregivers.

FDA Feedback Supports BLA Pathway for Sonelokimab in HS

MoonLake Immunotherapeutics shares promising updates on sonelokimab's efficacy for hidradenitis suppurativa.

Eli Lilly Trial Shows Superior Outcomes with Ixekizumab and Tirzepatide in Patients with PsA and Obesity

Results from the TOGETHER-PsA trial reveal that combining ixekizumab and tirzepatide significantly improves outcomes for psoriatic arthritis patients with obesity.

Rethinking Neoantigen Selection in High–Mutational Burden Cancers

Research reveals that structural changes in neoantigens enhance tumor rejection, offering new insights for personalized cancer immunotherapies.

Melasma Video Content on Social Media Has High Engagement but Low Reliability

A new study evaluates the quality and reliability of melasma posts on TikTok and Bilibili, highlighting gaps in treatment information and educational value.

Phase 2a Evaluation of Dual OX40L/TNFα Antibody Begins in HS

Navigator Medicines advances NAV-240 and NAV-242, targeting dual inflammation pathways for hidradenitis suppurativa in upcoming clinical trials.

Expert Panel Provides Clinical Guidance for the Use of Trifarotene in Malaysian Acne Care

Discover how trifarotene could enhance acne treatment in Malaysia, addressing both facial and truncal acne while improving hyperpigmentation and scarring.

New Clinical Insights Into Hair Loss Disorders and the Vitamin D Receptor

Discover how vitamin D receptor signaling influences hair follicle health and alopecia, revealing new therapeutic possibilities for hair loss management.